Sustained in vivo release from imprinted therapeutic contact lenses

In this paper, we demonstrate the successful in vivo extended release of a small molecular weight therapeutic, ketotifen fumarate (MW=425), from molecularly imprinted, therapeutic contact lenses. This is the first time that a steady, effective concentration of drug is maintained in the tear film fro...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of controlled release Vol. 157; no. 3; pp. 391 - 397
Main Authors:	Tieppo, A., White, C.J., Paine, A.C., Voyles, M.L., McBride, M.K., Byrne, M.E.
Format:	Journal Article
Language:	English
Published:	Kidlington Elsevier B.V 10-02-2012 Elsevier
Subjects:	Animals Anti-Allergic Agents - administration & dosage Anti-allergy bioavailability Biological and medical sciences Contact Lenses, Hydrophilic Controlled drug release Delayed-Action Preparations drug therapy drugs eye lens General pharmacology Hydrogel, Polyethylene Glycol Dimethacrylate Imprinted contact lenses Ketotifen - administration & dosage Ketotifen fumarate Male Medical sciences Molecular Imprinting molecular weight New Zealand White rabbit Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Rabbits Tears - chemistry Therapeutic contact lenses Ketotifen fumarate Controlled drug release Anti-allergy Imprinted contact lenses Molecular imprinting Therapeutic contact lenses Immunopathology Allergy Pharmaceutical technology Enzyme Controlled release form Enzyme inhibitor Antiasthma agent Antihistaminic In vivo Treatment Ketotifen Dosage form Antagonist Oxidoreductases Lipoxygenase H1 Histamine receptor
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In this paper, we demonstrate the successful in vivo extended release of a small molecular weight therapeutic, ketotifen fumarate (MW=425), from molecularly imprinted, therapeutic contact lenses. This is the first time that a steady, effective concentration of drug is maintained in the tear film from a contact lens for an extended period of time for the entire duration of lens wear. Poly(HEMA-co-AA-co-AM-co-NVP-co-PEG200DMA) soft contact lenses were prepared (100±5μm thickness, diameter 11.8mm, power zero), and a constant tear film concentration of 170±30μg/mL was measured for up to 26hrs in a New Zealand white rabbit model. The results showed a dramatic increase in ketotifen mean residence time (MRT) and bioavailability compared to topical drop therapy and drug soaked lenses. The MRT for imprinted lenses was 12.47±3.99hrs, ~4 and 50 fold greater than non-imprinted lenses and 0.035% eye drops (Zaditor®), respectively. Furthermore, AUC0–26hrs was 9 and 94 fold greater for imprinted lenses than non-imprinted lenses and eye drops, respectively. The results indicate that molecular imprinting provides an exciting rational engineering strategy for sustained release. It is clear that imprinted lenses are very promising combination devices and are much more effective and efficient delivery devices than eye drops. This is the first time that a steady, effective concentration of ketotifen fumarate is maintained in ocular tear film from an imprinted contact lens for an extended period of time. [Display omitted]
Bibliography:	http://dx.doi.org/10.1016/j.jconrel.2011.09.087 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
ISSN:	0168-3659 1873-4995
DOI:	10.1016/j.jconrel.2011.09.087